Waisman Center, University of Wisconsin-Madison, Rm 529, 1500 Highland Avenue, Madison, WI, 53705, USA.
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina Chapel Hill, 135 Dauer Dr, Chapel Hill, NC, 27599, USA.
J Autism Dev Disord. 2019 Jan;49(1):376-382. doi: 10.1007/s10803-018-3721-8.
Opioid use during pregnancy is associated with suboptimal pregnancy outcomes. Little is known about child neurodevelopmental outcomes. We examined associations between maternal opioid prescriptions preconception to delivery (peri-pregnancy) and child's risk of ASD, developmental delay/disorder (DD) with no ASD features, or ASD/DD with autism features in the Study to Explore Early Development, a case-control study of neurodevelopment. Preconception opioid prescription was associated with 2.43 times the odds of ASD [95% confidence interval (CI) 0.99, 6.02] and 2.64 times the odds of ASD/DD with autism features (95% CI 1.10, 6.31) compared to mothers without prescriptions. Odds for ASD and ASD/DD were non-significantly elevated for first trimester prescriptions. Work exploring mechanisms and timing between peri-pregnancy opioid use and child neurodevelopment is needed.
孕期使用阿片类药物与不理想的妊娠结局有关。关于儿童神经发育结局知之甚少。我们研究了母亲在受孕前至分娩期间(围孕期)开具的阿片类药物处方与儿童患 ASD、无 ASD 特征的发育迟缓/障碍 (DD) 或具有自闭症特征的 ASD/DD 的风险之间的关联,这项研究是对早期发育的探索性研究,是一项神经发育的病例对照研究。与没有处方的母亲相比,围孕期开具阿片类药物处方与 ASD 的几率增加 2.43 倍[95%置信区间 (CI) 0.99, 6.02],与具有自闭症特征的 ASD/DD 的几率增加 2.64 倍 (95% CI 1.10, 6.31)。与处方相比,孕早期开具处方的 ASD 和 ASD/DD 的几率升高,但无统计学意义。需要开展探索围孕期使用阿片类药物与儿童神经发育之间的机制和时间关系的相关工作。